Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms

Cancer Letters

Volumn 137, Issue 2, 1999, Pages 167-172

  Girgert, Rainer ^a   Vogt, Yvonne ^a   Becke, Daniela ^a   Bruchelt, Gernot ^b   Schweizer, Paul ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

HMG CoA reductase; L Ascorbic acid; Lovastatin; Neuroblastoma; Reactive oxygen

Indexed keywords

ASCORBIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN;

ARTICLE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEVALONIC ACID; NEUROBLASTOMA; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032927283     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00355-3     Document Type: Article

References (16)

1. Friedrich H. Vitamins. 1988;Walter de Gruyter, Berlin. pp. 931-1020.
2. Park C.H. Biological nature of the effect of ascorbic acids on the growth of human leukemic cells. Cancer Res. 45:1985;3969-3973.
3. Harwood H.J. Jr., Greene Y.J., Stacpoole P.W. Inhibition of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by ascorbic acid. An effect mediated by the free radical monodehydroascorbate. J. Biol. Chem. 261:1986;7127-7135.
4. Lenz M., Miehe W.-P., Vahrenwald F., Bruchelt G., Schweizer P., Girgert R. Cholesterol based antineoplastic strategies. Anticancer Res. 17:1997;1143-1146.
5. Maltese W.A., Defendini R., Green R.A., Sheridan K.M., Donley D.K. Suppression of mourn neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Clin. Invest. 76:1985;1748-1754.
6. Panini S.R., Schnitzer-Polokoff R., Spencer T.A., Sinensky M. Sterol-independent regulation of 3-Hydroxy-3-methylglutaryl-CoA-reductase by mevalonate in chinese hamster ovary cells. J. Biol. Chem. 264:1989;11044-11052.
7. Salmon S.E., Hamburger A.W., Soehnlein B.J., Durie B.G.M., Alberts D.S., Moon T.C. Quantitation of differential sensitivities of human tumor stem cells to anticancer drugs. N. Engl. J. Med. 298:1978;1321-1324.
8. Biedler J.L., Helson L., Spengler B.A. Morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:1973;2643-2652.
9. Bruchelt G., Gebhardt S., Baader S.L., Klinkenberg C.R., Niethammer D. Cytotoxic effects of ascorbic acid on neuroblastoma cells and its relationship to the catecholamine metabolism. Clin. Chem. Enzyme Commun. 6:1993;21-26.
10. Schaber M., O'Hara M., Garsky V., Mosser S., Berstrom J., Moores S., Marshall M., Friedman P., Dixon R., Gibbs J. Polyisoprenylation of Ras in vitro by a Farnesyl-Protein Transferase. J. Biol. Chem. 265:1990;14701-14704.
11. Martin D.M., Yee D., Carlson R.O., Feldman E.L. Gene expression of the insulin like growth factors and their receptors in human neuroblastoma cell lines. Mol. Brain. Res. 15:1992;241-246.
12. Janet T., Ludecke G., Otten U., Unsicker K. Heterogeneity of human neuroblastoma cell lines in their proliferative responses to basic FGF, NGF, and EGF: correlation with expression of growth factors and growth factor receptors. J. Neurosci. Res. 40:1995;707-715.
13. Girgert R., Marini P., Janessa A., Bruchelt G., Treuner J., Schweizer P. Inhibition of membrane localization of ras-p21-protein in N-ras transformed tumor cells by Lovastatin. Oncology. 51:1994;320-322.
14. Smets A., Lösberg C., Janssen M., Metwally A.M., Huiscamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 49:1989;2941-2944.
15. Baader S.L., Bruchelt G., Carmine T.C., Lode H.N., Rieth A.G., Niethammer D. Ascorbic acid mediated iron release from cellular ferritin and its relation to DNA strand break formation in neuroblastoma cells. J. Cancer Res. Clin. Oncol. 120:1994;415-421.
16. Handgretinger R., Anderson K., Lang P., Dopfer R., Klingebiel T., Schrappe M., Reuland P., Gillies S.D., Reisfeld R.A., Niethammer D. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer. 31A:1995;261-267.